ATE313540T1 - Heterozyklische verbindungen zur behandlung von harnwegserkrankungen - Google Patents
Heterozyklische verbindungen zur behandlung von harnwegserkrankungenInfo
- Publication number
- ATE313540T1 ATE313540T1 AT02782863T AT02782863T ATE313540T1 AT E313540 T1 ATE313540 T1 AT E313540T1 AT 02782863 T AT02782863 T AT 02782863T AT 02782863 T AT02782863 T AT 02782863T AT E313540 T1 ATE313540 T1 AT E313540T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- urinary tract
- heterocyclic compounds
- tract diseases
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001MI002060A ITMI20012060A1 (it) | 2001-10-05 | 2001-10-05 | Nuovi eterocilcli n-acilati |
PCT/EP2002/011282 WO2003031436A1 (en) | 2001-10-05 | 2002-10-07 | Heterocyclic compounds for use in the treatment of disorders of the urinary tract |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE313540T1 true ATE313540T1 (de) | 2006-01-15 |
Family
ID=11448476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02782863T ATE313540T1 (de) | 2001-10-05 | 2002-10-07 | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen |
Country Status (33)
Country | Link |
---|---|
US (2) | US20030181446A1 (de) |
EP (1) | EP1432701B1 (de) |
JP (1) | JP2005508952A (de) |
KR (1) | KR20040048930A (de) |
CN (1) | CN1564820A (de) |
AP (1) | AP1705A (de) |
AR (1) | AR036743A1 (de) |
AT (1) | ATE313540T1 (de) |
AU (1) | AU2002346979B9 (de) |
BR (1) | BR0213067A (de) |
CA (1) | CA2458456A1 (de) |
CO (1) | CO5570679A2 (de) |
CY (1) | CY1104991T1 (de) |
DE (1) | DE60208221T2 (de) |
DK (1) | DK1432701T3 (de) |
EA (1) | EA200400507A1 (de) |
EC (1) | ECSP045095A (de) |
ES (1) | ES2253568T3 (de) |
HK (1) | HK1067362A1 (de) |
HR (1) | HRP20040392A2 (de) |
HU (1) | HUP0401598A2 (de) |
IT (1) | ITMI20012060A1 (de) |
MA (1) | MA27067A1 (de) |
MX (1) | MXPA04002962A (de) |
NO (1) | NO20041833L (de) |
NZ (1) | NZ532511A (de) |
OA (1) | OA12663A (de) |
PL (1) | PL369763A1 (de) |
SI (1) | SI1432701T1 (de) |
TN (1) | TNSN04053A1 (de) |
WO (1) | WO2003031436A1 (de) |
YU (1) | YU27204A (de) |
ZA (1) | ZA200403356B (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR035521A1 (es) * | 2000-12-22 | 2004-06-02 | Lundbeck & Co As H | Derivados de 3-indolina y composicion farmaceutica que los comprende |
DK1408976T5 (da) * | 2001-07-20 | 2011-01-10 | Psychogenics Inc | Behandling af ADHD (Attention deficit hyperactivity disorder) |
ITMI20012060A1 (it) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
US20040058962A1 (en) * | 2002-06-14 | 2004-03-25 | Amedeo Leonardi | Phenylalkylamines and pyridylalkylamines |
US20040215284A1 (en) * | 2003-01-30 | 2004-10-28 | Recordati S.A. | Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists |
AR047759A1 (es) * | 2003-09-26 | 2006-02-22 | Vertex Pharma | Derivados de fenil - piperazina como moduladores de receptores muscarnicos |
RU2006124559A (ru) * | 2003-12-09 | 2008-01-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Производные нафтиридина и применение указанных производныхых в качестве модуляторов мускариновых рецепторов |
US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
WO2005090309A1 (en) * | 2004-03-12 | 2005-09-29 | Wyeth | 1,2-dihydroquinoline derivatives and method for using the same to treat hiv infection |
DE102005027168A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinoline |
WO2007134149A2 (en) * | 2006-05-11 | 2007-11-22 | Janssen Pharmaceutica N.V. | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors |
WO2008079427A1 (en) | 2006-05-11 | 2008-07-03 | Janssen Pharmaceutica N.V. | 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors |
FR2902790A1 (fr) * | 2006-06-27 | 2007-12-28 | Sanofi Aventis Sa | Derives d'urees de piperidine ou pyrrolidine,leur preparation et leur application en therapeutique |
PE20080344A1 (es) | 2006-06-27 | 2008-06-09 | Sanofi Aventis | Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1 |
PE20080212A1 (es) * | 2006-06-27 | 2008-04-25 | Sanofi Aventis | Derivados de ureas de piperidina o pirrolidina como moduladores de la 11b-hidroxiesteroide deshidrogenasa tipo 1 (11bhsd1) |
AU2007275736A1 (en) | 2006-07-19 | 2008-01-24 | Osurf (Ohio State University Research Foundation) | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
SI2178870T1 (sl) * | 2007-08-17 | 2018-11-30 | Lg Chem, Ltd. | Indolne in indazolne spojine kot inhibitor celične nekroze |
AU2009240417B2 (en) * | 2008-04-24 | 2014-06-26 | The Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
FR2969151B1 (fr) * | 2010-12-17 | 2016-11-04 | Oreal | Derives du 4-amino et leur utilisation pour la coloration d'oxydation des fibres keratiniques. |
CN105705501B (zh) * | 2013-09-09 | 2019-04-19 | 百时美施贵宝公司 | RORγ调节剂 |
CN105555768B (zh) * | 2013-09-20 | 2018-10-16 | 百时美施贵宝公司 | RORγ调节剂 |
AR107032A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
CN108299397B (zh) * | 2018-03-21 | 2019-01-29 | 佳木斯大学附属第一医院 | 一种用于降血压的活性药物及其制备方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1027611A (en) * | 1962-01-04 | 1966-04-27 | May & Baker Ltd | Phenoxy- and phenylthio-alkylamines and acid addition salts thereof |
GB1166538A (en) * | 1967-06-10 | 1969-10-08 | Pfizer Ltd | Substituted Tetrahydroquinolines |
US3983121A (en) * | 1974-07-01 | 1976-09-28 | Council Of Scientific And Industrial Research | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof |
US4011324A (en) * | 1976-01-20 | 1977-03-08 | Pfizer Inc. | Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents |
US4461896A (en) * | 1979-02-07 | 1984-07-24 | Norwich Eaton Pharmaceuticals, Inc. | 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids |
CH653021A5 (fr) * | 1981-04-24 | 1985-12-13 | Delalande Sa | Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant. |
US4585773A (en) * | 1984-07-11 | 1986-04-29 | Bristol-Myers Company | Isoindolinyl-alkyl-piperazines |
EP0189612B1 (de) * | 1984-12-21 | 1992-11-04 | Duphar International Research B.V | Arzneimittel mit psychotroper Wirkung |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5641504A (en) * | 1988-06-09 | 1997-06-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolinoleate |
PT99989A (pt) * | 1991-01-09 | 1994-05-31 | Alza Corp | Dispositivos biodegradaveis e composicoes para libertacao difusivel de agentes |
US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
JPH05117276A (ja) * | 1991-10-23 | 1993-05-14 | Sumitomo Pharmaceut Co Ltd | 新規な3環性キノキサリンジオン誘導体 |
US5629019A (en) * | 1992-02-27 | 1997-05-13 | Alza Corporation | Formulations with hydrophobic permeation enhancers |
DE69326848T2 (de) * | 1992-05-13 | 2000-01-27 | Alza Corp | Oxybutynin zur transdermalen Verabreichung |
US5512293A (en) * | 1992-07-23 | 1996-04-30 | Alza Corporation | Oral sustained release drug delivery device |
US5573776A (en) * | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
US5533971A (en) * | 1993-09-03 | 1996-07-09 | Alza Corporation | Reduction of skin irritation during electrotransport |
IT1270993B (it) * | 1994-03-18 | 1997-05-26 | Recordati Chem Pharm | Derivati chinzolilamminici attivi come alfa-antagonisti |
FR2729144A1 (fr) * | 1995-01-06 | 1996-07-12 | Smithkline Beecham Lab | Nouvelles diamines, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu' agents anti-arythmiques |
US5859014A (en) * | 1995-06-09 | 1999-01-12 | Syntex (U.S.A.) Inc. | Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists |
US5780058A (en) * | 1995-07-21 | 1998-07-14 | Alza Corporation | Oral delivery of discrete units |
US6096339A (en) * | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
JP4073961B2 (ja) * | 1996-10-01 | 2008-04-09 | 協和醗酵工業株式会社 | 含窒素複素環化合物 |
CA2220649C (en) * | 1996-12-03 | 2007-02-13 | F. Hoffmann-La Roche Ag | 4-hydroxy-piperidine derivatives |
EP0846683B1 (de) * | 1996-12-03 | 2001-09-19 | F. Hoffmann-La Roche Ag | 4-Hydroxypiperidinderivate |
US6281227B1 (en) * | 1996-12-13 | 2001-08-28 | Aventis Pharma Deutschland Gmbh | Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
AU5609798A (en) * | 1996-12-20 | 1998-07-17 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
US6169086B1 (en) * | 1997-01-27 | 2001-01-02 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives |
JP2001512110A (ja) * | 1997-08-01 | 2001-08-21 | レコルダチ エッセ.ア.,ケミカル アンド ファーマシューティカル カンパニー | 1,4−ジ置換ピペラジン |
IT1293804B1 (it) * | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | Diarilalchilpiperazine attive sulle basse vie urinarie |
US6039977A (en) * | 1997-12-09 | 2000-03-21 | Alza Corporation | Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods |
PL343249A1 (en) * | 1998-03-26 | 2001-07-30 | Shionogi & Co | Indole derivatives with antiviral activity |
US6174547B1 (en) * | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
US6306861B1 (en) * | 1999-07-30 | 2001-10-23 | Recordati S.A. Chemical And Pharmaceutical Company | Thienopyrancecarboxamide derivatives |
US6403594B1 (en) * | 1999-10-18 | 2002-06-11 | Recordati, S.A. Chemical And Pharmaceutical Company | Benzopyran derivatives |
US6365591B1 (en) * | 1999-10-18 | 2002-04-02 | Recordati, S.A., Chemical And Pharmacueticals Company | Isoxazolecarboxamide derivatives |
AR035521A1 (es) * | 2000-12-22 | 2004-06-02 | Lundbeck & Co As H | Derivados de 3-indolina y composicion farmaceutica que los comprende |
US20030060513A1 (en) * | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
ITMI20012060A1 (it) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
-
2001
- 2001-10-05 IT IT2001MI002060A patent/ITMI20012060A1/it unknown
-
2002
- 2002-10-04 AR ARP020103760A patent/AR036743A1/es not_active Application Discontinuation
- 2002-10-07 OA OA1200400088A patent/OA12663A/en unknown
- 2002-10-07 ES ES02782863T patent/ES2253568T3/es not_active Expired - Lifetime
- 2002-10-07 EA EA200400507A patent/EA200400507A1/ru unknown
- 2002-10-07 BR BR0213067-0A patent/BR0213067A/pt not_active IP Right Cessation
- 2002-10-07 AP APAP/P/2004/002997A patent/AP1705A/en active
- 2002-10-07 EP EP02782863A patent/EP1432701B1/de not_active Expired - Lifetime
- 2002-10-07 YU YU27204A patent/YU27204A/sh unknown
- 2002-10-07 DK DK02782863T patent/DK1432701T3/da active
- 2002-10-07 KR KR10-2004-7004948A patent/KR20040048930A/ko not_active Application Discontinuation
- 2002-10-07 NZ NZ532511A patent/NZ532511A/en unknown
- 2002-10-07 DE DE60208221T patent/DE60208221T2/de not_active Expired - Fee Related
- 2002-10-07 JP JP2003534419A patent/JP2005508952A/ja not_active Withdrawn
- 2002-10-07 US US10/266,088 patent/US20030181446A1/en not_active Abandoned
- 2002-10-07 PL PL02369763A patent/PL369763A1/xx not_active Application Discontinuation
- 2002-10-07 AU AU2002346979A patent/AU2002346979B9/en not_active Ceased
- 2002-10-07 AT AT02782863T patent/ATE313540T1/de not_active IP Right Cessation
- 2002-10-07 SI SI200230244T patent/SI1432701T1/sl unknown
- 2002-10-07 HU HU0401598A patent/HUP0401598A2/hu unknown
- 2002-10-07 CA CA002458456A patent/CA2458456A1/en not_active Abandoned
- 2002-10-07 US US10/266,104 patent/US20030162777A1/en not_active Abandoned
- 2002-10-07 WO PCT/EP2002/011282 patent/WO2003031436A1/en active IP Right Grant
- 2002-10-07 CN CNA028197283A patent/CN1564820A/zh active Pending
- 2002-10-07 MX MXPA04002962A patent/MXPA04002962A/es unknown
-
2004
- 2004-03-11 MA MA27571A patent/MA27067A1/fr unknown
- 2004-04-02 TN TNP2004000053A patent/TNSN04053A1/en unknown
- 2004-05-04 NO NO20041833A patent/NO20041833L/no not_active Application Discontinuation
- 2004-05-04 CO CO04040886A patent/CO5570679A2/es not_active Application Discontinuation
- 2004-05-04 ZA ZA200403356A patent/ZA200403356B/en unknown
- 2004-05-04 HR HR20040392A patent/HRP20040392A2/hr not_active Application Discontinuation
- 2004-05-05 EC EC2004005095A patent/ECSP045095A/es unknown
- 2004-10-11 HK HK04107812A patent/HK1067362A1/xx not_active IP Right Cessation
-
2006
- 2006-03-03 CY CY20061100304T patent/CY1104991T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE313540T1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
ATE440866T1 (de) | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten | |
DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
DE602004028763D1 (de) | Te zur behandlung von virenerkrankungen | |
DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
ATE472325T1 (de) | Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen | |
ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
ATE448219T1 (de) | Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen | |
DE60322451D1 (de) | 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung | |
ATE384522T1 (de) | Medikamente zur chemotherapeutischen behandlung von erkrankungen | |
ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
DE60236743D1 (de) | Zur behandlung androgenabhängiger krankheiten | |
DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
DE60218375D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen | |
ATE327752T1 (de) | Aryl- (oder heteroaryl-) azolylcarbynolderivatve zur behandlung von harninkontinenz | |
DE60328494D1 (de) | Verbessertes system zur behandlung der stressbedingten harninkontinenz | |
DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
ATE312104T1 (de) | Verbindungen zur behandlung von beeinträchtigten fundischen entspannung | |
DE60016047D1 (de) | Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten | |
DE60216457D1 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
ATE430577T1 (de) | Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1432701 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |